Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Day One Biopharmaceuticals, Inc. - Common Stock (NQ: DAWN )

12.26 +0.05 (+0.41%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Day One Biopharmaceuticals, Inc. - Common Stock

< Previous 1 2 Next >
Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Biotech Investing: How PRV’s Can Unlock Major Opportunities (OSTX, DAWN, SWTX, PTCT)
Via AB Newswire
Exposures Product Safety
Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate Priorities
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Reports Third Quarter 2024 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Oversubscribed $175.0 Million Private Placement
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Sale of Priority Review Voucher for $108 Million
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Two New Appointments to Board of Directors
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
Data subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual Meeting 
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
Priority review granted with PDUFA target action date of April 30, 2024 
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Pricing of Public Offering of Common Stock
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Proposed Public Offering of Common Stock
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029
EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END 
Via FinancialNewsMedia
Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.